Latest News

DaVita (DVA) moved back into focus after reporting first quarter 2026 results that exceeded expectations, lifting its earnings outlook and highlighting progress in its value-based Integrated Kidney Care platform expansion. See our latest analysis for DaVita. DaVita’s recent earnings beat and Integrated Kidney Care expansion come after a strong run, with the 90 day share price return of 35.90% and 1 year total shareholder return of 51.78% pointing to building momentum around the current...

The AI Infrastructure Stocks screener focuses on the hardware backbone that makes AI possible, at a time when global data, energy and inflation trends are front of mind for markets. With manufacturing PMIs firming in the US, services growth mixed in Europe and the UK, and central banks still wrestling with inflation, many investors are looking for business models tied to real assets and cash flow. This screener concentrates on companies that help build and run the specialized data centers,...

Why IDEAYA Biosciences Stock Is Back in Focus IDEAYA Biosciences (IDYA) is drawing renewed investor attention after enrolling the first patient in a Phase 1 trial that pairs IDE892 with IDE397 in MTAP-deleted solid tumors. The study centers on cancers such as non-small cell lung and pancreatic, where MTAP deletions are relatively common and no approved targeted therapies currently exist. This development is making IDEAYA Biosciences stock a focal point for investors watching early clinical...

Regulation is back in focus, and for many investors that can feel like a moving target. With new rules, shifting fiscal policy, changing interest rate expectations, and fresh economic data, some technology stocks appear better positioned than others to handle tighter oversight and evolving compliance demands. This Regulation-Resilient Technology Companies screener filters for large tech firms that already talk explicitly about regulation or compliance and that currently score well on measures...

General Motors (GM) stock is back in focus after the company moved beyond traditional auto manufacturing by agreeing to repurpose plants for defense production while ramping up energy storage, battery technology, and advanced driver assistance offerings. See our latest analysis for General Motors. At a share price of $78.95, General Motors has seen a 4.43% 90 day share price return and a 65.54% 1 year total shareholder return. This performance has coincided with growing attention on its...

Earlier in June 2026, HEICO Corporation amended its revolving credit agreement, lifting the facility to US$2.20 billion, extending its maturity to June 11, 2031, revising the rate structure to reflect HEICO’s long-term debt ratings, and releasing certain subsidiaries from guarantee obligations tied to both the credit facility and specific bond issues. The company also reported record fiscal second-quarter 2026 results and raised its semiannual cash dividend by 8% to US$0.13 per share,...

Atmos Energy stock reacts to recent performance data Atmos Energy (ATO) has drawn investor attention after recent performance figures highlighted a mix of share price moves and fundamental data, prompting closer scrutiny of how its gas distribution and pipeline operations align with current expectations. See our latest analysis for Atmos Energy. The recent 1 day share price return of 0.88% has not offset the 30 day share price decline of 2.94% and 90 day decline of 5.78%. However, longer term...

UCB (ENXTBR:UCB) stock is in focus after new Brain Communications data on KYGEVVI for early onset TK2 deficiency highlighted improved survival and functional outcomes, along with acceptable tolerability in treated patients. See our latest analysis for UCB. The latest KYGEVVI data arrives as UCB shares trade at €255.0, with an 8.88% year to date share price return and a 51.64% total shareholder return over 1 year. This points to strong long term momentum alongside more modest recent gains. If...

Belite Bio (BLTE) has drawn fresh attention after completing a rolling New Drug Application submission to the U.S. FDA for tinlarebant, a potential treatment for Stargardt disease type 1, alongside recent insider share sales. See our latest analysis for Belite Bio. Belite Bio's latest NDA milestone and insider transactions come after a mixed stretch of trading, with a 9.81% 1 month share price return and year to date share price performance that is down 5.34%. This sits alongside a very large...

FIGS (FIGS) has recently drawn investor attention after its shares moved sharply, with the stock up 6.8% in the latest session but down over the past week and month. That short term volatility is prompting closer scrutiny. See our latest analysis for FIGS. Looking past the latest move, FIGS has a 1-year total shareholder return of 108.13% alongside a 90-day share price return that declined 23.66%. This suggests recent momentum has cooled after a strong longer term run as investors reassess...

In recent days, Alkami Technology, Inc. highlighted the past success of its partnership with Landmark Credit Union, showing how Landmark accelerated its digital transformation and upgraded both retail and business member experiences using Alkami’s cloud-based platform. An important takeaway is that Landmark Credit Union scaled its commercial banking program using Alkami’s business and commercial capabilities, indicating how the platform can support deeper penetration into small-business and...

Guardant Health (GH) is back in focus after the U.S. Food and Drug Administration approved its Guardant360 CDx liquid biopsy as a companion diagnostic for Boehringer Ingelheim’s newly approved HERNEXEOS lung cancer therapy. See our latest analysis for Guardant Health. The recent FDA approval arrives as momentum in Guardant Health's stock has been strong, with a 90-day share price return of 55.58% and a 1-year total shareholder return of 174.69%. This indicates that investors are reassessing...

Kaspi.kz (NasdaqGS:KSPI) has drawn fresh attention after confirming a special cash dividend, with an ex dividend date tied to a payout of $1.74266 per share, together with a KZT 850 distribution per common share. See our latest analysis for Kaspi.kz. Against this backdrop, Kaspi.kz’s share price has moved to $86.0, with a 1 day share price return of 2.99% and a 7 day share price return of 3.28%. The 30 day share price return is down 6.05% and the 90 day share price return is 15.97%, alongside...

Kalpataru Projects International Limited ( NSE:KPIL ) stock is about to trade ex-dividend in 3 days. Typically, the...

BYD stock performance sets the stage for valuation questions BYD (SEHK:1211) has come under pressure recently, with the stock down about 17% over the past month and about 26% over the past 3 months, prompting fresh scrutiny of its current valuation. Those moves sit against a longer track record that includes a year to date decline of about 23% and a total return decline of about 41% over the past year, even as the company reports sizeable revenue and net income. See our latest analysis for...

Woolworths Group (ASX:WOW) is back in focus after renewed confidence in its supermarket operations, as investors assess how price freezes on own-brand staples and cost-cutting efforts might influence the stock during ongoing cost pressures. See our latest analysis for Woolworths Group. Over the past year Woolworths Group has shifted back into favour, with a 33.78% year to date share price return and a 29.15% total shareholder return over 12 months. This suggests momentum has been building as...

Hioki E.E. Corporation ( TSE:6866 ) stock is about to trade ex-dividend in 3 days. The ex-dividend date is two business...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Shift4 Payments (FOUR) recently drew fresh attention after partnering with Lydian to let merchants accept Tether (USDT) while still settling in local currency, broadening its crypto offering alongside expectations for event driven payment volumes. See our latest analysis for Shift4 Payments. Despite the crypto partnership and expectations around event driven volumes, Shift4 Payments’ share price has been volatile, with a 1 day share price return of 14.35% and a year to date share price return...

Jiayin Group (NasdaqGM:JFIN) has wrapped up FY 2025 with fourth quarter revenue of C¥1,090.2 million and basic EPS of C¥1.95, alongside trailing 12 month revenue of C¥6.2 billion and EPS of C¥29.41, all against a backdrop of 45.4% trailing earnings growth over the past year. Over recent periods the company has seen quarterly revenue move from C¥1,404.5 million and EPS of C¥5.18 in Q4 2024 to C¥1,775.6 million and EPS of C¥10.11 in Q1 2025, before reaching the latest Q4 print. This sets the...

Targa Resources (TRGP) has drawn investor attention after its stock closed at $266.32, with recent returns mixed between the past month and past 3 months, and a year-to-date gain alongside longer-term strength. See our latest analysis for Targa Resources. Over the past year, Targa Resources has combined strong momentum, with a 42.59% year to date share price return and a very large 5 year total shareholder return of 564.25%, even though the 30 day share price return is down 3.77%, suggesting...

If you are wondering whether Waters is priced fairly or if the stock leans more toward opportunity or caution, this article walks through the key valuation checks that may matter most to you. Waters recently closed at US$369.18, with returns of 3.4% over the last week, 7.8% over the last month, a decline of 3.3% year to date, and a 5.5% gain over the past year. This provides useful context before considering what the current price might imply. Recent coverage has described Waters as a mature...